APVO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Aptevo Therapeutics's net margin of -49.65%. Aptevo Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 1979.21%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Aptevo Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Aptevo Therapeutics is more attractive than NovaBay Pharmaceuticals.

Aptevo Therapeutics has a beta of 5.753, which suggesting that the stock is 475.252% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aptevo Therapeutics's net income of -$6.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

OptiNose has a net margin of -- compared to Aptevo Therapeutics's net margin of -1.61%. Aptevo Therapeutics's return on equity of -- beat OptiNose's return on equity of --.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 1979.21%. On the other hand OptiNose has an analysts' consensus of $18.00 which suggests that it could grow by 98.46%. Given that Aptevo Therapeutics has higher upside potential than OptiNose, analysts believe Aptevo Therapeutics is more attractive than OptiNose.

Aptevo Therapeutics has a beta of 5.753, which suggesting that the stock is 475.252% more volatile than S&P 500. In comparison OptiNose has a beta of -0.873, suggesting its less volatile than the S&P 500 by 187.316%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptiNose offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. OptiNose pays out -- of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than OptiNose quarterly revenues of $22.4M. Aptevo Therapeutics's net income of -$6.3M is lower than OptiNose's net income of -$360K. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while OptiNose's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus 1.18x for OptiNose. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Aptevo Therapeutics's net margin of -2357.27%. Aptevo Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 1979.21%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Aptevo Therapeutics has higher upside potential than Palatin Technologies, analysts believe Aptevo Therapeutics is more attractive than Palatin Technologies.

Aptevo Therapeutics has a beta of 5.753, which suggesting that the stock is 475.252% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Aptevo Therapeutics's net income of -$6.3M is lower than Palatin Technologies's net income of -$2.4M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Aptevo Therapeutics's net margin of -18.58%. Aptevo Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 1979.21%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Aptevo Therapeutics has higher upside potential than Retractable Technologies, analysts believe Aptevo Therapeutics is more attractive than Retractable Technologies.

Aptevo Therapeutics has a beta of 5.753, which suggesting that the stock is 475.252% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Aptevo Therapeutics's net income of -$6.3M is lower than Retractable Technologies's net income of -$1.9M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.